Under one in 10 patients who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it publishes its initial guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the jabs that can aid individuals in losing significant weight, explains the organization.
Skinny Jab Supply Crisis
Despite the present best projected outlook, the production of these medications would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.
The advice encourages countries and companies to widen availability, by measures like licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Function
These medications imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals consume fewer calories.
People usually see weight reduction within a few weeks of starting on the weekly injections.
Studies points to users may regain a significant portion after a year of discontinuing the treatment, as their typical appetite resume.
Being overweight or obese raises your chance for contracting health problems, including diabetes, heart disease, stroke, and specific malignancies.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
